BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

by · The Cerbat Gem

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 3,503 shares, a decline of 76.1% from the June 30th total of 14,642 shares. Based on an average daily volume of 5,583 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Analysis on BGLC

Institutional Investors Weigh In On BioNexus Gene Lab

An institutional investor recently raised its position in BioNexus Gene Lab stock. DRW Securities LLC increased its position in shares of BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 226.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,830 shares of the company’s stock after purchasing an additional 33,179 shares during the quarter. DRW Securities LLC owned 2.02% of BioNexus Gene Lab worth $189,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.85% of the company’s stock.

BioNexus Gene Lab Stock Down 2.0%

Shares of BGLC stock traded down $0.03 during trading hours on Friday, hitting $1.51. 4,816 shares of the company were exchanged, compared to its average volume of 5,025. The stock has a market capitalization of $3.65 million, a price-to-earnings ratio of -1.02 and a beta of 4.08. BioNexus Gene Lab has a one year low of $1.07 and a one year high of $8.98. The business’s 50-day simple moving average is $2.06 and its two-hundred day simple moving average is $2.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.69 and a current ratio of 6.53.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter. BioNexus Gene Lab had a negative net margin of 54.70% and a negative return on equity of 37.43%. The firm had revenue of $0.02 million during the quarter.

About BioNexus Gene Lab

(Get Free Report)

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.

Featured Stories